Abstract: The present invention is directed to monoclonal antibodies and fragments thereof directed to LRP5/6 that find use in the prevention and treatment of cardiac remodeling and cancer. Also disclosed are methods for using such monoclonal antibodies in the prevention and treatment of such diseases.
Type:
Grant
Filed:
April 30, 2012
Date of Patent:
July 29, 2014
Assignee:
Vanderbilt University
Inventors:
Ethan Lee, Pampee P. Young, Josiane Eid
Abstract: The present invention relates to antibodies and related molecules that specifically bind to neurokinin B. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including pre-eclampsia, hypertension, inflammation, asthma, gastrointestinal disorders, anxiety, depression, addiction, or pain. The invention also relates to nucleic acid molecules encoding anti-neurokinin B antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.
Abstract: Targeting molecules for use in delivering biological agents to epithelial tissue are disclosed. Upon delivery, the biological agent(s) may remain within an epithelial cell or may undergo transepithelial transport via transcytosis. The targeting molecules may be used, for example, for the delivery of therapeutic agents.
Type:
Grant
Filed:
January 9, 1998
Date of Patent:
December 25, 2007
Assignee:
Plantbodies Corporation
Inventors:
Mich B. Hein, Andrew C. Hiatt, John H. Fitchen
Abstract: The present invention provides a method for detecting the presence of cytomegalovirus (CMV) in a fetal sample by determining the presence of anti-hsp70 antibodies present in the fetal sample. The invention further provides a method for monitoring CMV infection in a human fetus. In another embodiment, the invention provides a method for detecting CMV in a cord blood sample of a neonate.
Abstract: The subject invention relates to the use of ascorbic acid and derivatives thereof in stabilizing radiolabeled proteins and peptides against oxidation loss of radiolabel and autoradiolysis. Ascorbic acid is added after radiolabeling, including any required incubation period, but prior to patient administration.
Abstract: The present invention relates to the use of insoluble forms of recombinant proteins in a flow cytometric immunofluorescence assay for the detection of given antibodies.
Abstract: An oral dosage composition for intestinal delivery of a therapeutic agent comprising:(A) a therapeutic agent selected from the group consisting of a drug compound, a biologically active peptide and a vaccine; and(B) an intestinal absorption enhancing effective amount of purified Vibrio cholera zonula occludens toxin.
Abstract: There is disclosed a method of treating a mammal infected with a macrophage pathogen comprising administering an effective amount of a TGF-.beta. antagonist. Macrophage pathogens include any pathogenic microorganism that replicates within macrophage cell hosts as their exclusive or primary host cells. TGF-.beta. antagonists include blocking antibodies specific for a human TGF-.beta., soluble TGF-.beta. receptors, protease inhibitors that inactivate a protease responsible for activating a precursor TGF-.beta. into an active, mature TGF-.beta., and combinations thereof.